These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26836192)

  • 41. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.
    Brown BM; Sohrabi HR; Taddei K; Gardener SL; Rainey-Smith SR; Peiffer JJ; Xiong C; Fagan AM; Benzinger T; Buckles V; Erickson KI; Clarnette R; Shah T; Masters CL; Weiner M; Cairns N; Rossor M; Graff-Radford NR; Salloway S; Vöglein J; Laske C; Noble J; Schofield PR; Bateman RJ; Morris JC; Martins RN;
    Alzheimers Dement; 2017 Nov; 13(11):1197-1206. PubMed ID: 28501451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.
    Schöll M; Almkvist O; Bogdanovic N; Wall A; Långström B; Viitanen M; Nordberg A
    J Alzheimers Dis; 2011; 24(3):495-506. PubMed ID: 21297272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuropathology and biochemistry of early onset familial Alzheimer's disease caused by presenilin-1 missense mutation Thr116Asn.
    Sutovsky S; Smolek T; Turcani P; Petrovic R; Brandoburova P; Jadhav S; Novak P; Attems J; Zilka N
    J Neural Transm (Vienna); 2018 Jun; 125(6):965-976. PubMed ID: 29404783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Schöll M; Ossenkoppele R; Strandberg O; Palmqvist S; ; Jögi J; Ohlsson T; Smith R; Hansson O
    Brain; 2017 Sep; 140(9):2286-2294. PubMed ID: 29050382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature.
    Nikisch G; Hertel A; Kiessling B; Wagner T; Krasz D; Hofmann E; Wiedemann G
    Eur J Med Res; 2008 Dec; 13(12):579-84. PubMed ID: 19073399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. De Novo PS1 Mutation (Pro436Gln) in a Very Early-Onset Posterior Variant of Alzheimer's Disease Associated with Spasticity: A Case Report.
    Agüero P; Sainz MJ; Téllez R; Lorda I; Ávila A; García-Ribas G; Rodríguez PP; Gómez-Tortosa E
    J Alzheimers Dis; 2021; 83(3):1011-1016. PubMed ID: 34366350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia.
    Castellano CA; Nugent S; Paquet N; Tremblay S; Bocti C; Lacombe G; Imbeault H; Turcotte É; Fulop T; Cunnane SC
    J Alzheimers Dis; 2015; 43(4):1343-53. PubMed ID: 25147107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tau pathology and cognitive reserve in Alzheimer's disease.
    Hoenig MC; Bischof GN; Hammes J; Faber J; Fliessbach K; van Eimeren T; Drzezga A
    Neurobiol Aging; 2017 Sep; 57():1-7. PubMed ID: 28577411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro.
    Cash MK; Rockwood K; Fisk JD; Darvesh S
    Neurobiol Aging; 2021 Jul; 103():31-41. PubMed ID: 33789210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.
    Chien DT; Szardenings AK; Bahri S; Walsh JC; Mu F; Xia C; Shankle WR; Lerner AJ; Su MY; Elizarov A; Kolb HC
    J Alzheimers Dis; 2014; 38(1):171-84. PubMed ID: 23948934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo reactive astrocyte imaging using [
    Kong Y; Cao L; Wang J; Zhuang J; Xie F; Zuo C; Huang Q; Shi K; Rominger A; Li M; Wu P; Guan Y; Ni R
    J Neurol Sci; 2024 Jul; 462():123079. PubMed ID: 38878650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
    Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
    Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
    Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
    Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.
    Fuller JT; Cronin-Golomb A; Gatchel JR; Norton DJ; Guzmán-Vélez E; Jacobs HIL; Hanseeuw B; Pardilla-Delgado E; Artola A; Baena A; Bocanegra Y; Kosik KS; Chen K; Tariot PN; Johnson K; Sperling RA; Reiman EM; Lopera F; Quiroz YT
    J Prev Alzheimers Dis; 2019; 6(2):112-120. PubMed ID: 30756118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
    Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
    Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.